Matthews O. Bradley, PhD, has held key positions within the pharmaceutical industry for over 25 years and has extensive expertise in drug discovery and strategic drug development with a focus on target selection, drug proof of concept, pre-clinical pharmacology and toxicology, and IND/Phase I/II/III/NDA preparation in numerous therapeutic areas including Parkinson’s. Dr. Bradley has been the founder or co-founder of five previous biopharmaceutical companies where he has served in various executive R&D and board functions. His work in those companies resulted in in-licenses, out-licenses, 18 patents, and numerous drugs discovered and developed through regulatory submissions.
Prior to these companies, Dr. Bradley spent 12 years at Merck and Co. Before joining Merck, Dr. Bradley was a senior staff fellow at the National Cancer Institute of the National Institutes of Health. Dr. Bradley received a BA in biology from The University of Pennsylvania and a PhD in biological sciences from Stanford University.